More than reducing work force and implementing other cost-cutting measures, drugmakers should focus on making new products to compensate for financial losses, the Financial Times writes. Companies that opted to purchase smaller firms to secure rights to new drugs have benefited from such deals, but those moves will not solve drugmakers' overall financial problems, the paper says.

Related Summaries